Latest filings (excl ownership)
8-K
Material Modifications to Rights of Security Holders
26 Jul 24
8-K
New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system
26 Jul 24
DEF 14A
Definitive proxy
1 Jul 24
8-K
Material Modifications to Rights of Security Holders
24 Jun 24
S-3
Shelf registration
21 Jun 24
8-K/A
Entry into a Material Definitive Agreement
20 Jun 24
PRE 14A
Preliminary proxy
20 Jun 24
8-K
Entry into a Material Definitive Agreement
17 Jun 24
D
$15.15 mm in equity / options / securities to be acquired, sold $15.15 mm, 5 investors
31 May 24
D
$26.85 mm in equity / options / securities to be acquired, sold $26.85 mm, 4 investors
31 May 24
8-K
Material Modifications to Rights of Security Holders
23 May 24
8-K
MyMD Pharmaceuticals Secures Strategic Investments
21 May 24
10-Q
2024 Q1
Quarterly report
15 May 24
8-K
Departure of Directors or Certain Officers
18 Apr 24
8-K
Entry into a Material Definitive Agreement
8 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K/A
Amendments to Articles of Incorporation or Bylaws
26 Mar 24
8-K
Entry into a Material Definitive Agreement
7 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
13 Feb 24
8-K
Regulation FD Disclosure
6 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced
19 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Oct 23
8-K
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
4 Oct 23
8-K
Departure of Directors or Certain Officers
8 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Regulation FD Disclosure
14 Aug 23
8-K
MyMD Pharmaceuticals Phase 2 Trial Update
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
1 Aug 23
8-K
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline
31 Jul 23
DEFA14A
Additional proxy soliciting materials
21 Jul 23
8-K
Other Events
14 Jul 23
ARS
2022 FY
Annual report to shareholders
30 Jun 23
DEF 14A
Definitive proxy
30 Jun 23
PRE 14A
Preliminary proxy
20 Jun 23
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
9 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Regulation FD Disclosure
12 Apr 23
8-K
Departure of Directors or Certain Officers
5 Apr 23
Latest ownership filings
3
Stephen Friscia
28 Jun 24
3
Initial statement of insider ownership
30 May 24
SC 13D
PharmaCyte Biotech, Inc.
30 May 24
3
Mitchell Glass
16 May 24
SC 13G
Global X Management CO LLC
14 Feb 24
SC 13G/A
Iroquois Capital Management, LLC
14 Feb 24
4
Paul Rivard
24 Aug 23
4
Paul Rivard
18 Aug 23
4
Christopher C Chapman JR
9 Jun 23
4
Adam Kaplin
9 Jun 23
4
Jude Uzonwanne
9 Jun 23
4
Christopher C Schreiber
9 Jun 23
4
Joshua Silverman
9 Jun 23
4
CRAIG EAGLE
9 Jun 23
4
Billy Joe White
9 Jun 23
4
Paul Rivard
9 Jun 23
4
Christopher C Chapman JR
5 Apr 23
SC 13G/A
Iroquois Capital Management, LLC
14 Feb 23
4
Paul Rivard
8 Dec 22
SC 13D
DUFFEY SAMUEL S
8 Sep 22
SC 13G/A
Iroquois Capital Management, LLC
23 Feb 22
SC 13G/A
INTRACOASTAL CAPITAL, LLC
11 Feb 22
SC 13G/A
MAINFIELD ENTERPRISES INC
11 Jan 22
4
Joshua Silverman
29 Nov 21
4
Paul Rivard
24 Nov 21
4
Adam Kaplin
15 Oct 21
4
Christopher C Schreiber
15 Oct 21
4
Billy Joe White
15 Oct 21
4
Jude Uzonwanne
15 Oct 21
4
CRAIG EAGLE
15 Oct 21
4
Joshua Silverman
15 Oct 21
4
Christopher C Chapman JR
15 Oct 21
4
Paul Rivard
15 Oct 21
SC 13D
Williams Caroline C
27 Apr 21
3
Caroline C Williams
26 Apr 21
4
CRAIG EAGLE
22 Apr 21
3
CRAIG EAGLE
22 Apr 21
4
Adam Kaplin
21 Apr 21
3
Adam Kaplin
21 Apr 21
4
Christopher C Schreiber
21 Apr 21